IL34 and metabolic dysfunction-associated steatotic liver disease: IL-34 was reported to increase in the circulation of biopsy-proven NAFLD patients with the progression of fibrosis, being mainly secreted by HSCs, as shown with immunohistochemistry in liver specimens obtained from NAFLD patients [75].